Global Macrolide Drugs Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Macrolide Drugs Sales Market Report 2024
Market Analysis and InsightsGlobal Macrolide Drugs Market
The macrolide drugs are a group of antibiotics produced by various strains of Streptomyces (spore forming bacteria that grow slowly in soil or water as a branching filamentous mycelium similar to that of fungi) and have a complex chemical (macrocyclic) structure. They act by inhibiting protein synthesis, specifically by blocking the 50S ribosomal subunit. They are broad spectrum antibiotics.
Due to the COVID-19 pandemic, the global Macrolide Drugs market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, 14-Membered Ring Agents accounting for % of the Macrolide Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Macrolide Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Macrolide Drugs include Abbott Laboratories, Akorn, Eli Lilly & Co., Fresenius Kabi, Gland Pharmm, Sirolimus, Neo Química, Tacorolimus and Macrolide Pharmaceuticals, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Macrolide Drugs Scope and Market Size
The global Macrolide Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Macrolide Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
14-Membered Ring Agents
15-Membered Ring Agents
16-Membered Ring Agents
Ketolides
Hospitals
Clinics
Hospitalshospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Abbott Laboratories
Akorn
Eli Lilly & Co.
Fresenius Kabi
Gland Pharmm
Sirolimus
Neo Química
Tacorolimus
Macrolide Pharmaceuticals
Mylan
Pfizer
Sanofi
Merck & Co.
Sandoz International
Teva Pharmaceutical Industries
WOCKHARDT
The macrolide drugs are a group of antibiotics produced by various strains of Streptomyces (spore forming bacteria that grow slowly in soil or water as a branching filamentous mycelium similar to that of fungi) and have a complex chemical (macrocyclic) structure. They act by inhibiting protein synthesis, specifically by blocking the 50S ribosomal subunit. They are broad spectrum antibiotics.
Due to the COVID-19 pandemic, the global Macrolide Drugs market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, 14-Membered Ring Agents accounting for % of the Macrolide Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Macrolide Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Macrolide Drugs include Abbott Laboratories, Akorn, Eli Lilly & Co., Fresenius Kabi, Gland Pharmm, Sirolimus, Neo Química, Tacorolimus and Macrolide Pharmaceuticals, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Macrolide Drugs Scope and Market Size
The global Macrolide Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Macrolide Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
14-Membered Ring Agents
15-Membered Ring Agents
16-Membered Ring Agents
Ketolides
Segment by Application
Hospitals
Clinics
Hospitalshospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Abbott Laboratories
Akorn
Eli Lilly & Co.
Fresenius Kabi
Gland Pharmm
Sirolimus
Neo Química
Tacorolimus
Macrolide Pharmaceuticals
Mylan
Pfizer
Sanofi
Merck & Co.
Sandoz International
Teva Pharmaceutical Industries
WOCKHARDT
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices